reserved.
The anti-leukemia potential of natural killer (NK) cells has been evaluated in 40 patients transplanted for chronic myelogenous leukemia (CML) t o determine whether differences in NK cell function were correlated with subsequent leukemic relapse. Cells from patients and their donors were tested in "Cr release assays against fully allogeneic CML targets and against cultured K562 targets; cells from 26 patients were tested against host-derived CML targets that were cryopreserved before transplantation. Cultured CML targets (K562) were highly susceptible t o lysis by freshly isolated peripheral blood lympocytes (PBL) and to a greater degree by PBL cultured in medium containing interleukin-2 (IL-2) in all assays performed. In contrast, noncultured CML targets were lysed only by IL-2-activated cells from a subset of patients. When present, lytic activity t o CML targets was detectable as early as 3 weeks after bone marrow transplantation, and remained positive throughout the posttransplant period. Optimal lytic activity developed within the first week of culture and required 2250 U/mL of IL-2 in the culture medium. Lytic activity t o N E RATIONALE for using bone marrow transplanta-0 tion (BMT) as a treatment for leukemia is that this approach permits the administration of total body irradiation (TBI) and chemotherapeutic drugs designed to eliminate leukemic cells at doses that would otherwise induce a permanent marrow aplasia. The administration of donor marrow is required to restore hematopoiesis and immune function. Evidence also suggests that the efficacy of an allogeneic BMT as a treatment for leukemia is not strictly limited to the conditioning regimen, but may also involve the activity of immunocompetent cells transplanted with the marrow that eliminates residual host leukemic cells. The evidence for a such a graft-versus-leukemia (GVL) effect in humans is strongly suggested by the reduced incidence of relapse reported after HLA-matched marrow grafts in comparison with grafts from identical twins.' In a number of fully allogeneic and host-derived CML targets appeared to be mediated by CD16' and CD56' cells but not by CD3' cells. Lysis of allogeneic CML targets was variable, but patients could be divided into t w o groups: those with and those without lytic activity t o the majority of targets tested. The basis for the differences in lytic activity could not be ascribed t o target susceptibility t o lysis, the proportion of NK cells in the cultures, or t o the phenotype of the NK cell subsets in the cultures. When tested in parallel, the lytic activity of donor and recipient cultures against hostderived CML targets was highly correlated, suggesting that there may be inherent differences in the ability of NK cells t o recognize CML targets. The risk of relapse for patients who failed t o generate lytic activity against host-derived CML targets was significantly increased over that for patients with lytic activity against host leukemia. These data indicate that posttransplant immunotherapy with IL-2 designed to activate NK cells will likely augment the graft-versus-leukemia potential of the graft. 0 1990 by The American Society of Hematology.
studies the presence of acute and/or chronic graft-versushost disease (GVHD)'-4 also has been found to be associated with a decreased incidence of relapse in patients transplanted for leukemia. Consonant with this observation have been studies reporting an increase in leukemic relapse in recipients of marrow from which mature T cells have been removed for GVHD prevention.'-' However, the GVHD and GVL potential of marrow grafts can be separated in animal models,'0." and augmentation of GVHD by abbreviations in GVHD prophylaxis or by increasing the dose of immunocompetent T cells administered with the graft has resulted in increased mortality without a reduction in the incidence of leukemia relapse in a recent human trial." Several possible mechanisms have been proposed to explain the GVL e f f e~t .~ One of these possibilities involves the activation of nonspecific effector systems such as natural killer (NK) cells during GVHD. There is a substantial body of evidence that supports the role of N K cells in defense against leukemia. In murine models, an association between NK activity and susceptibility to leukemias has been ~h o w n '~. '~ and resistance to leukemia can be transferred with cloned N K cells.'' In humans there appears to be an increased incidence of hematopoietic malignancies in individuals with low NK activity,l6 and impaired N K functions are commonly seen in patients with leukemia and preleukemic Because high numbers of circulating cells with NK phenotype and full functional activity have been demonstrated early following all types of BMT,'*-*' we have concentrated our efforts to determine whether these NK cells can function as anti-leukemia effectors during the posttransplant period. For our initial studies we have examined peripheral blood mononuclear (PBMC) obtained a t intervals after transplant from a series of patients transplanted for chronic myelogenous leukemia (CML). We have compared the lytic activities of resting and interleukin-2 (IL-2)-activated patient cells with cells from the bone marrow donors against host-derived and/or allogeneic CML targets. We have examined the kinetics of activation, the target cell specificity, and the phenotype of the anti-leukemia effectors. We have further assessed whether the potential for anti-leukemia activity might be associated with posttransplant CML relapse.
MATERIALS AND METHODS

Patients.
All of the 40 patients included in this study were transplanted for Philadelphia chromosome positive (Ph'+) CML from HLA identical donors. The median age of the patients was 29 with a range of 3 to 45 years, and consisted of 24 males and 16 females. Thirty-two patients were transplanted for CML in first chronic phase, four patients were in second chronic phase, and three patients were transplanted in accelerated phase (as defined by additional chromosomal abnormalities). One patient was transplanted with greater than 30% marrow myeloblasts after a period during which treatment with Idarubicin (Erbamont Inc, Adria Laboratories, Dublin, OH) and cytosine arabinoside resulted in disappearance of the Ph' chromosome, and is thus considered to have been in blast crises. All patients had previously received hydroxyurea; four patients had received a-interferon, and four patients received chemotherapy with either Idarubicin and cytosine arabinoside (three cases) or Adriamycin, Vincistine, and prednisone (one case) before conditioning for BMT. Pretransplant conditioning consisted of hyperfractionated TBI (1,375 cGy to 1,500 cGy) followed by cyclophosphamide (60 mg/kg x 2).
Thirty-five of the patients were studied after receiving marrow depleted of T cells by treatment with soybean agglutinin and sheep erythrocytes (SBA-E-BM) as previously described.26 Donor peripheral blood was added back to the marrow in five of these cases to achieve a T-cell dose of 1.0 to 1.5 x 105/kg (SBA-E-+ T). Two patients received marrow that was partially depleted of T cells by treatment with SBA (SBA-) alone, and three patients received conventional, unseparated marrow grafts. Four grafts were secondary transplants after graft failure or leukemia relapse.
Recipients of conventional marrow grafts received short course methotrexate (MTX) with cyclosporine posttransplant as GVHD pro phyla xi^.'^ Recipients of T-cell depleted BMT received no posttransplant GVHD prophylaxis, and one recipient of partially T-cell depleted marrow received cyclosporine alone. No patient developed chronic GVHD, and only one patient developed acute, fatal GVHD (grade 111) after transplantation of SBA-E-BM, to which donor PBMC had been added back. One patient experienced late graft failure, without detection of Ph'+ cells before death at week 13. Clinical relapse occurred in nine patients, and was defined as the reappearance in the marrow of metaphases containing the Ph' chromosome and the development of hematologic changes characteristic of the underlying disease. Isolated appearance of Ph' in the marrow has occurred in four patients. These patient characteristics are summarized in Table 1 (see Table 7 for presentation in detail).
These studies were performed with informed consent following protocol approval by the Institutional Review Board.
Preparation of leukemic and normal targets. Before transplantation, mononuclear leukemic cells were isolated from patient peripheral blood or spleen on gradients of Ficoll-Hypaque (Lymphoprep, Nyegaard & Co, Oslo, Norway). Peripheral blood from one patient who relapsed after transplant in the blast crises of CML was obtained for use as targets only. For some samples, further fractionation was performed by incubation on nylon wool columns for 60 minutes at 37OC, and separation of the eluted cells on discontinuous step gradients of five different densities of Percoll (Pharmacia, Uppsala, Sweden) ranging from 40% to 60% Percoll. In two cases, PBMC were depleted of mature cells by immune rosetting with chromium chloride treated human erythrocytes as described." The PBMC were treated with a combination of monoclonal antibodies (MoAbs) (in ascites form), all of which were adjusted to a final dilution Differentials of Wright-Giemsa stained cytocentrifuge preparations of the cells were performed before and/or after cryopreservation. Only those preparations containing 275% myeloid cells were used as targets. The target from the blast crises CML patient was fractionated on a Percoll gradient and consisted of greater than 98% blasts by morphology. SBA-E-BM cells were obtained from normal bone marrow donors and were cryopreserved on the day of transplant. Leukemic cells and SBA-E-BM were cryopreserved in aliquots of approximately 5 x IO6 cells/mL in a freezing solution of 90% fetal bovine serum (FBS) and 10% dimethylsulfoxide (DMSO) and were stored in liquid nitrogen. PBMC from marrow donors, patients after transplantation, and normal controls were separated on FicollHypaque gradients and were cryopreserved in a freezing solution of 20% FBS, 10% DMSO, and 70% RPMI-1640.
Heparinized peripheral blood was separated on Ficoll-Hypaque gradients and was depleted of monocytes by plastic adherence before assay of NK lytic function. LAK assays were performed on freshly isolated or cryopreserved PBMC after 3 to 7 days of culture at 37OC in a humidified atmosphere of 5% CO,. The cells were cultured at a concentration of 1 x lo6 cells/mL in RPMI 1640 medium supplemented with 25 mmol/L HEPES, 100 U/mL penicillin, 100 pg/mL streptomycin, 2 mmol/L L-glutamine, 10% heat-inactivated pooled human serum (M.A. Bioproducts, Walkersville, MD), with human recombinant IL-2 (kindly provided by the Cetus Corp, Emeryville, CA). NK and LAK lytic activites were measured in standard 4 hour 5'Cr release assays at multiple effector to target cell ratios as previously described." The K562 cell line, which was established from the pleural effusion of a patient in CML blast crises, was used as target for fresh NK cell activity and was included in each assay of LAK activity. K562 targets were labeled in a total volume of 0.5 mL RPMI-10% FBS for 1 to 2 hours at 37OC with 125 pCi of Sodium
NK and lymphokine activated killer cell (LAK).
use only. IL-2activated cells were treated with mouse MoAbs plus low toxicity baby rabbit complement (Pel Freez, Rogers, AR) or with complement alone as previously de~cribed.~' OKT3 (anti-CD3) was used as culture supernatant from the hybridoma cell line obtained from the American Type Culture Collection and was kindly provided by Dr Robert Evans (Rosewell Park Memorial Institute, Buffalo, NY). Leul l b ascites were a kind gift of Steve Brown (University of Kentucky, Lexington). NKHI, ascites were a generous gift from Dr J. Ritz (Dana Faber Cancer Insitute, Boston, MA), and OKT8 was purchased from Orthro Diagnostics (Raritan, NJ). The antibodies were used at a previously determined optimal dilution in a volume of 0.1 mL/106 treated cells. OKT3 was used undiluted, OKT8 was diluted 1:20, Leul l b was used at a dilution of 150, and NKHI, was used at a dilution of 1:125. After treatment of effector cells, all preparations were adjusted to the concentration of the complement control before assay. In preliminary experiments, direct immunofluorescence analysis of cells depleted in this manner showed 1% to 3% contamination with cells bearing the relevant antigen.
RESULTS
Antibody plus complement depletions.
Recovery of NK cell numbers and function after transplantation for CML. W e have previously reported the early regeneration of NK cells and NK and L A K activity in leukemic patients after T-cell depleted and conventional BMT.2S,30 Figure 1 shows that NK cell recovery is also very rapid in the subgroup of patients transplanted for CML. The proportion of peripheral CD56' N K cells is elevated in most patients through the first year posttranspiant and is highest during the first 6 months (Fig 1, panel A) . Two-color immunofluorescence analysis showed that nearly all of the CD56+ cells coexpress CD16, and that there were few CD3/CD56 coexpressing cells (less than 2%) (not shown). These N K cells a r e fully functional as measured by lytic activity to K562 targets. Normal to high activity to K562 was maintained throughout the posttransplant period (Fig 1, panel B). The activity of the N K cells could be markedly enhanced by 3 to 7 days of culture in medium containing 
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Activity of posttransplant NK and LAK cells to noncultured leukemia targets. We used pretransplant C M L cells that had been cyropreserved immediately after isolation to determine the susceptibility of noncultured leukemic cells to posttransplant N K and LAK lytic activity. Consistent with previously reported data from normal controls and patients with l e~k e m i a ,~~.~~ freshly isolated posttransplant peripheral blood lymphocytes (PBL) were unable to lyse noncultured chronic phase C M L targets, whereas cells that were incubated for 3 to 7 days in medium containing IL-2 could lyse these targets. Because the C M L cells separated on FicollHypaque gradients are not a homogeneous population, nor did all patients have the same proportion of cell types at the time of sample acquisition, we needed to determine the degree to which cell preparations from different patients were sensitive to lysis by the IL-2-activated cells. Furthermore, we needed to determine whether sensitivity to lysis was a function of the leukemia or merely the stage of cellular differentiati~n.~~.~' For this purpose we compared normal PBMC, PMBC from C M L patients, early myeloid cellenriched PBMC from C M L patients, and normal bone marrow for sensitivity to lysis by IL-2-activated effectors. The data in Fig 2 represent the highest degree to which each C M L target was lysed when tested against two or more different effectors. In no experiment was there greater than 10% specific lysis of cryopreserved PBMC from normal individuals. In contrast, greater than 10% lysis of PBMC from 20 of 22 patients with C M L was seen (median = 17%, range 2% to 40%). In an attempt to increase the homogeneity of the leukemic target population, peripheral blood or spleen cells from 14 patients were enriched for immature myeloid cells, either on discontinuous Percoll gradients (n = 12) or by depletion of mature cellular elements using a cocktail of MoAbs and immune rosetting ( N = 2). Although these targets also showed varying degrees of sensitivity to lysis, all were lysed greater than lo%, with a median specific lysis of 29% (range 11% to 69%). The most susceptible targets were those with the highest proportion of blasts and promyelocytes (most enriched in the layer between 40% and 45% Percoll). This increased susceptibility to lysis was not merely a function of the presence of immature myeloid cells, since the highest specific lysis of SBA-E-BM cells (enriched for early myeloid cells) from five different normal donors was only 11%. The lytic activity of the effectors used in these experiments toward C M L targets was always markedly less than that to K562 targets (median = 79.2%, E:T = 25:1, N = 3 1) even when tested a t lower effector to target cell ratios.
Optimization of culture conditions for the generation of anti-leukemia activity. Our previous studies had shown that optimal generation of lytic activity to cultured tumor targets could be obtained with 100 U/mL IL-2." However, since higher concentrations of IL-2 might be required to maximize activity to a more resistant target, dose response experiments were performed in three patients. Consistent with our previous findings, concentratons of IL-2 greater than 100 U/mL did not significantly increase lytic activity to K562; however, lytic activity to C M L targets was increased with concentrations of IL-2 2 250 U/mL (not shown). Thereafter, subsequent cultures were supplemented with 250 U/mL IL-2.
Our previous data had also indicated that optimal LAK activity was generated after 3 to 4 days of culture of PBMC from patients less than 5 months after transplant, but required a longer culture period (5 to 7 days) for normal controls and patients greater than 5 months p~sttransplant.~' It has been suggested that the kinetics of LAK activation may be dependent on the type of target used as well as the use only.
For personal at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From concentration of IL-2 in the cultures.36 Therefore, we varied the day of assay to determine a t what time anti-leukemia activity developed and the degree to which this activity could be maintained in cultures that were supplemented with fresh medium and kept a t optimal cell concentrations (1 to 2 x lo6 cells/mL). Anti-leukemia activity was detectable as early as day 3 of culture and could be maintained for as long as 3 weeks. The activity did not appear to be consistently enhanced by culture for more than 1 week (not shown). For subsequent experiments, assays were performed after 3 to 7 days of culture.
Lytic activity to CML targets with time after transplantation. The results shown in Fig 1 show that although the proportion of N K cells within the lymphoid population of CML patients declines with time after transplant, N K and LAK lytic activity to K562 targets remains at a high level. We assessed whether lytic activity to noncultured C M L targets varied with time after transplant. The data in Table 2 are from multiple LAK assays of PBMC from six representative patients toward allogeneic C M L targets and C M L targets of host origin. Cells from three of these patients had lytic activity to host-derived C M L that was present throughout the posttransplant course (0.8 to 9 months), while IL-2-activated cells from three additional patients failed to lyse host-derived C M L targets at all times after transplant (0.8 to 12 months). The IL-2-activated cells from all six patients were able to lyse allogeneic C M L targets. There was no clear association of lytic activity toward K562 with lytic activity to C M L targets in these or in other experiments not shown.
Comparison of lytic activity by effectors from patients and their bone marrow donors. The data in Table 3 are from 15 experiments in which IL-2-activated cells from the patients and their HLA identical bone marrow donors (cyropreserved a t the time of transplant) were tested in parallel. The lytic activity of donor and patient cultures to host C M L targets was very similar (excluding donorrecipient pair no. 806, r = 32). Five donor-recipient pairs had lytic activity toward the host-derived C M L targets whereas there was no LAK activity to host targets by seven donor-recipient pairs. The donor-recipient activities were discordant in only two instances. The failure of donor or patient effectors to lyse host CML targets was not likely due to the insensitivity of these targets to lysis, since targets that were not lysed by patient or donor effectors could be lysed by effectors from at least one other unrelated patient in every instance tested ( N = 5). Although there were fewer parallel studies performed, the data suggest a positive correlation between patient and donor lytic activity to specific allogeneic CML targets (r = .83, N = 6). In contrast, there was no significant correlation between lytic activity of IL-2-activated cultures from donors and patients to K562 targets, nor was there a correlation of K562 lytic activity with activity to noncultured CML targets.
Lysis of tumor targets by IL-2-activated PBMC has been shown to be primarily mediated by CD3-cells bearing CD16 and/or CD56 in both normal individuals and cancer patient^.^^.^^ However, CD3+ cells, which do or do not express CD16 or CD56, can also contribute to these a~t i v i t i e s .~~.~~ We have previously demonstrated that LAK activity to cultured tumor targets during the posttransplant period is primarily mediated by cells with an NK phenotype (CD3-, CD16+, CD56+).'j To confirm that the LAK activity against noncultured C M L targets was due to IL-2-activiated N K cells and not T lymphocytes, we performed depletion experiments using MoAbs plus complement. The results in Table 4 show that lysis of either host-derived or fully allogeneic C M L targets was only minimally affected by removal of CD3' or CD8+ cells, whereas removal of CD16+ cells, CD56+ cells, or both cell types consistently reduced, or eliminated the lysis of these targets. The phenotype of the anti-CML effector was the same in patients tested early ( 5 2 months) or from 1 to 5 years after transplant. A similar pattern of depletion was seen when K562 cells were used as targets, although in cultures with a high degree of lytic activity, cytotoxicity was not completely eliminated by the treatments. These data indicate that the lytically active anti-leukemia effector does have an NK phenotype and not a T-cell phenotype, and that Phenotype of anti-leukemia effector.
use NK cells with anti-leukemia potential can be found throughout the posttransplant period. Activity of LAK efectors from patients toward multiple CML targets. Clones exhibiting major histocompatibility complex nonrestricted killing often display a spectrum of target cell recognition that may not be detectable in the bulk populations from which they are derived.m42 We assessed whether the IL-2-activated cells from individual patients would preferentially lyse certain CML targets. The data in Table 5 show the reactivity of effectors from nine patients who, over the course of this study, had been tested to targets from five or more fully allogeneic CML patients, including target cells isolated from the patient in CML blast crises (greater than 98% myeloblasts), target 791. Effectors from each patient were able to lyse one or more CML targets, and conversely, IL-2-activated cells from each of the patients failed to lyse one or more CML targets. In every instance, targets that were not lysed by effectors from the patients shown in the table were lysed by effectors from other patients or controls. IL-2-activated cells from four of the patients tested (nos. 753,701,790,806) had low or no lytic activity to the majority of targets tested, while LAK effectors from five patients (nos. 681, 684, 852, 580, 675) had lytic activity (210%) to most targets. Although we have not ruled out in every case the potential contribution of in vivo activated HLA allospecific cytotoxic T lymphocytes (CTL) to the activities seen, the data in Table 4 indicate that lytic activity to fully allogeneic C M L targets can be mediated by N K cells. These data suggest that there may be preferential target cell recognition by LAK effectors from a single individual, but also show that the LAK effectors from some patients have an overall greater capacity to lyse C M L targets than those from other patients. Immunojuorescence analysis of IL-2-activated cells. Cells with NK and LAK activity can be divided into several subpopulations based on the expression of CD3 or CD8 in combination with either CD16, CD56, or both antigens. 43 The possibility was considered that there may be differences in NK cell mediated lytic activity to C M L targets based on the number of NK cells or on the relative proportion of N K cell subpopulations in the cultures. We performed two-color immunofluorescence analysis of cells from eight patients with and without anti-CML activity before and/or after 4 to 7 days of culture. The IL-2-activated cells in these experiments were tested against homogeneous targets of myeloblasts isolated from a blast crisis C M L patient. In most of the five patients whose cells were phenotyped before and after culture, CD16+ cells and, to a greater extent, CD56+ cells were selectively expanded. The CD16+ cells nearly all coexpressed CD56 both before and after culture. However, after culture as many as 50% of the CD56+ cells were CD16-. There were marked differences in the proportion of cells with N K phenotype in the cultures; however, these differences did not appear to correlate with the degree of anti-CML activity. Indeed, the culture that consisted of almost exclusively CD56' cells (patient no. 675) failed to lyse the CML target, while the highest specific lysis was by a culture (patient no. 852) that contained only 16% CD56+ cells. We also did not detect a correlation between the proportion of CD3+CD56+, CD3+CD16+, or CD8+CD56+ cells and anti-leukemia activity (Table 6) .
Correlation of anti-CML activity with clinical features. We analyzed the data to determine whether LAK activity to noncultured CML targets or cultured C M L targets (K562) was correlated with leukemic relapse. Of the 40 patients studied, nine patients subsequently relapsed with their leukemia (3 to 59 months after transplant), and five additional patients were found to have minor populations of hostderived Ph'+ cells in their marrow but had no clinical evidence of leukemia in the periphery.
For this analysis, 210% lysis of host targets or of any allogeneic CML target a t any time after transplant was considered positive for anti-leukemia activity. We found no correlation between clinical relapse and the degree of lytic activity to K562 targets ( N = 40) or the capacity to lyse fully allogeneic C M L targets ( N = 37). However, when lysis of host C M L targets ( N = 26) was examined there was a significant correlation with clinical relapse. IL-2-activated cells from 8 of the 9 patients who clinically relapsed had been tested against host C M L targets; cells from seven of these patients did not lyse host CML. clinical relapse failed to lyse host C M L targets (chi2 = 9.7, P = .0002) (Fig 3) . Kaplan-Meier estimates of the probability of relapse for patients who did nor did not lyse host CML targets are shown in Fig 4. The probability of clinical relapse for patients with cytolytic activity to host targets was 7% at 39 months after transplant compared with 72% for those who failed to lyse this target (P = .002). Classification into the category of patients without lytic activity did not simply reflect fewer tests to host targets in relapsed patients.
Relapsed patients were tested 2.9 + 2.0 times (range 1 to 6 ) to host targets with consistent negative results, which is nearly identical to the mean number of tests performed in nonrelapsed patients, 3.1 + 2.1 (range 1 to 9) ( Table 7 ).
All four patients with minor populations of Ph'+ marrow metaphases but no evidence of peripheral disease had lytic activity to host-derived C M L targets. Not all patients with Ph' ever, a significant proportion subsequently d0.44-46 If all patients with cytogenetic relapse are considered as relapsed, the probability of relapse estimates becomes 38% for those with lytic activity and 67% for those without lytic activity to host C M L targets (P = 0.45) (not shown). A number of other factors must also be considered when evaluating C M L relapse post-BMT, including patient age, interval from diagnosis to transplantation, the type of transplant (T-cell depleted v T-cell replete), and most significantly, the disease status a t the time of tran~plantation.~-~.~' Our study involves a relatively small number of patients who are heterogenous for these characteristics. Listed in Table 7 are the clinical and experimental data for each of these patients. Because of the small numbers, statistically valid multivariate analysis could not be performed. However, it would appear from the data that as expected, 2 of the 3 patients with advanced disease (acclerated-phase CML, blastic CML) who were tested to host targets fell into the group of patients who experienced clinical relapse. If these patients (unique patient nos. Patients transplanted for C M L were selected for study since these patients present for transplant with clinically active disease, and thus each patient's own leukemic cells can be harvested and cryopreserved before transplantation. Previous studies have demonstrated that freshly isolated leukemia targets from patients with acute leukemia are usually resistant to N K cell mediated lysis, but can be lysed to varying degrees by N K cells that have been activated by culture in medium containing IL-2 or interfer~n.~'.~~,~~.~~.~~ C irculating myeloid progenitors in patients with C M L are much more susceptible to the suppressive effects of N K cells56 than to NK-mediated cytolytic activity. The clonogenic leukemic precursor may be the more biologically relevant target of in vivo activity; however, in our experience adequate colony growth from pretransplant cyropreserved peripheral C M L cells was not consistent. Therefore, to study autologous leukemia, we used the predominant circulating cells of C M L patients in the chronic phase that are differentiated to the metamyelocyte, or myelocyte stage in standard 5'Cr release assays. While not as susceptible as leukemic myeloblast^,^'.^^ these targets were lysed to a measurable degree (Fig 2) . We have also included in our studies the standard cultured Ph'+ leukemic cell target, K562, and in most assays, a noncultured target from a patient who relapsed after BMT in the blast crises of CML. Each of these targets represent a homogeneous immature population that can better be used to compare the activity of cultures from different patients and from the same patient over time.
In previous studies, we and others have shown that N K cell populations exhibiting normal cytolytic activity against K562 targets emerge as early as 18 to 21 days after either a conventional or a T-cell-depleted marrow graft. 22-25.30 This study confirms these findings in a group of patients transplanted for CML, patients who, in the chronic phase of the disease, are usually found to have normal numbers of N K cells that exhibit abnormally low lytic activity against cultured tumor target^.^^.^',^',^^
The N K cells of C M L patients developing after marrow transplantation are also distinguished by the fact that their activity can be augmented by as few as 3 days of culture in medium containing IL-2, rather than the 3 weeks required in some nontransplanted C M L patient^.^"" The normal cytotoxic activity of the NK cells emerging after transplant (Fig  1 ) may reflect their derivation from donor progenitors.
Contrary to the findings in nontransplanted patients with CML, our results and those of Livnat et all8 have identified no correlations between the level of lytic activity against K562 and either the presence of residual host leukemic cells or the risk of subsequent relapse.
As expected, noncultured CML cells either from blast crisis or chronic phase patients were not susceptible to lysis by freshly isolated PBL. However, IL-2 activation did induce lytic activity to these targets. When present, lytic activity to both host-derived and fully allogeneic C M L targets was found throughout the posttransplant period and could be detected in patients from 3 weeks to 5 years after transplant. The data from antibody plus complement treatments of the IL-2-activated cultures indicates that after transplantation the primary effector cell active against both host-derived and fully allogeneic C M L targets were CD16+, CD56', CD3-N K cells.
Distinguishing features of N K cell mediated anti-tumor activity versus those of cytotoxic T lymphocytes include the N K cell's capacity to recognize target cells without prepriming and without MHC restriction. Activation of NK cells with IL-2 increases the range of targets that can be lysed, but most noncultured, nontransformed cells are not susceptible targets. It has only been at the clonal level that target cell specificity of M H C nonrestricted killers has been dem~nstrated.~'.~~ Such target preferences are seen both in CD3+ and CD3-clones and is not blocked by antibodies to CD3.4' Thus, N K cell target recognition does not seem to involve T-cell receptors. Heterogeneity has also been described for N K cell clones isolated after BMT, in that clones selected for lytic activity to the patients own leukemia have not lysed all other leukemias of the same type.42*54 The basis for target cell recognition by N K cells is a subject of intense investigation. To date, no single receptor on the N K cell or structure on the target cell has been identified that is critical for this interaction.
While target specificity has generally not been described in bulk cultured LAK cells, certain individual tumor targets appear to be more or less susceptible to lysis. In our study we found that a single, homogeneous CML target isolated from a patient in blast crisis was lysed to markedly varying degrees by IL-2-activated cells from different patients as well as cells from normal controls (0 to 60% specific lysis). Of more interest was the variation in the lytic activity of IL-2-activated cells from patients tested to five or more different targets (Table 5 ). Patients could be divided into two groups, those who lysed the majority of the targets tested, and those who failed to lyse these targets. However, in certain instances, broadly reactive effectors failed to lyse C M L targets (Table 3) suggests that alteration in the host environment induced by the patient's disease or its treatment does not adversely affect the functional development of N K cell precursors. The data in Table 3 also suggest that a proportion of donors lack circulating precursors of IL-2-activated cells with the ability to react to HLAmatched C M L targets derived from their siblings.
In an attempt to determine if the variable lytic activity was due to different proportions of N K cells in the cultures or whether there were differences in the subpopulations of N K cells, we performed two-color immunofluorescence analysis before and after culture. We failed to find phenotype differences that correlated with activity, based on the number of NK cells or their coexpression of CD3, CD8, CD56, or CD16. These data suggest that there may be inherent differences in N K cells between individuals in their ability to recognize and/or lyse C M L targets and that these differences are not reflected by a single cell surface phenotype. Alternatively there may be interactions between cells in the cultures, ie, T cells and N K cells, which may affect the development of lytic activity to C M L targets. Clonal analysis of NK cell subsets mediating anti-CML activity are currently underway to help clarify these issues.
IL-2 activated cells from all of the patients readily lysed K562 targets and the lytic activity to allogeneic CML targets varied widely, dependent on the target tested; therefore, it was not surprising that the only significant correlation we found between LAK activity and leukemia relapse was with lytic activity to host-derived CML targets. Seven of eight patients tested before reappearance of leukemic cells in the periphery, failed to lyse the host-derived CML target compared with 4 of 18 patients who did not clinically relapse. In surviving patients, the actuarial risk of relapse for patients who failed to generate lytic activity against host CML cells (72%) was significantly increased over that for patients whose LAK cells did lyse host CML targets (7%, P = .002).
Clearly other factors contribute to the possibility for relapse in these patients. Small numbers prevent multivarient analysis; however, from the data presented in Table 7 it can be seen that a greater proportion of patients at high risk for relapse due to the advance stage of their disease did fall into the relapsed group. It is also clear from the data in Table 7 that high risk CML did not in itself prevent the development of anti-leukemia activity since IL-2-activated cells from one such patient (UPN 804) did lyse host leukemia targets.
Several recent studies have shown that the reappearance, or failure to eradicate Ph'+ marrow metaphases is not invariably associated with clinical relapse after BMT but in a large proportion of cases, subsequent clinical relapse does Six patients in this series who were tested to host C M L had reappearance of Ph'+ marrow metaphases in the absence of clinical disease; two of these patients (UPN 742, UPN 806) have progressed to clinical disease and both failed to lyse host C M L targets when tested from the first month posttransplant. Of interest are the four patients with antihost CML activity who have persisted for 1 year or more with minor populations of Ph' + host-derived marrow metaphases but have not shown additional signs of leukemic recurrence. All of these patients did develop anti-host C M L cytolytic reactivity. These observations suggest the possibility that immunologic mechanisms, possibly involving NK mediated anti-leukemia activity may be inhibiting full-scale emergence of the leukemia.
The basis for the failure of IL-2-activated cells from certain patients and their donors to lyse host CML targets is unknown. It is possible that NK cells capable of lysing HLA-matched or autologous CML cells represent a specialized population of effectors that is regulated in number or function by genetic or acquired characteristics of the individual. The possibility that the inability to lyse host-derived CML targets reflects failed engraftment of donor NK cells must also be considered. Preliminary data from two patients, neither of whom lyses host CML targets, indicated that while marrow metaphases and phytohemagglutinin stimulated peripheral blood metaphases were predominantly donor, both patients had N K cells that were predominantly (291%) of host origin. In one case (UPN 806, Table 3 ), this cytogenetic finding also served to explain a discordance between the high lytic activity of the donor's own IL-2-activated cells and the minimal IL-2-activated lytic activity of cells isolated from the patient posttransplant, this patient subsequently relapsed clinically. Analyses of additional patients, and sequential studies over time will be required to determine the validity of this association.
The fact that NK cells emerging early in the posttransplant period have lytic activity towards allogeneic and cultured C M L targets in the majority of patients is encouraging. It is likely that our use of "Cr release assays to assess anti-leukemia activity underestimates the potential of these N K cells to suppress leukemia regrowth. Data from our primate model indicate that infusion of IL-2 during weeks 1 through 4 posttransplant period can augment the activity of the regenerating NK cells but does not promote T-cell activity during this period.58 Therefore, in vivo immunotherapy with IL-2 during the posttransplant period may be of value to augment the GVL potential of the transplanted marrow.
